Skip to main content
Questions to ask your health care provider

Talking openly with your health care provider is important in making informed decisions about your treatment journey. These suggested questions are a starting point to help you learn more about your cancer care and treatment. You are also encouraged to ask additional questions that are important to you.

General Questions 

1

Have we uncovered everything we can about my lung cancer?

2

Does my lung cancer have any biomarkers like the BRAF V600E mutation?

3

If yes, am I eligible for any of the targeted therapies for lung cancer?

4

How will we know if the treatment is working?

5

What side effects should I expect on treatment?

6

Is there anything I can do to help manage side effects?

7

How do I manage potential fevers as a side effect?

8

What symptoms or side effects should I tell you about right away?

Testing Questions

1

What is comprehensive biomarker testing?

2

Are you doing biomarker testing on my lung cancer?

3

Is it appropriate to do a comprehensive biomarker test while waiting for other test results?

4

Will I need special tests such as imaging scans and blood tests, and how often?

Important Safety Information

TAFINLAR and MEKINIST may cause serious side effects, including:

Risk of new cancers. TAFINLAR, when used in combination with MEKINIST, may cause a type of skin cancer called cutaneous squamous cell carcinoma, keratoacanthoma, basal cell carcinoma, or melanoma. Talk with your health care provider about your risk for these cancers. Check your skin and tell your health care provider right away about any skin changes, including a new wart, skin sore, or reddish bump that bleeds or does not heal, or a change in size or color of a mole.

Your health care provider should check your skin before you start treatment, and every 2 months while on treatment, to look for any new skin cancers. Your health care provider should continue to check your skin for 6 months after you stop taking TAFINLAR and MEKINIST.

Approved Uses

TAFINLAR and MEKINIST are prescription medicines that can be used in combination to treat people with a type of skin cancer called melanoma:

  • that has spread to other parts of the body (metastatic) or cannot be removed by surgery (unresectable), and

  • that has a certain type of abnormal “BRAF” (V600E or V600K mutation-positive) gene

TAFINLAR and MEKINIST are prescription medicines that can be used in combination to help prevent melanoma that has a certain type of abnormal “BRAF” gene from coming back after the cancer has been removed by surgery.

Click or scroll to see IMPORTANT SAFETY INFORMATION AND APPROVED USES